AU2014368548B2 - Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features - Google Patents

Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features Download PDF

Info

Publication number: AU2014368548B2
Authority: AU; Australia
Prior art keywords: vortioxetine; activity; treatment; nalmefene; opioid antagonist
Prior art date: 2013-12-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2014368548A

Other languages

English (en)

Other versions

AU2014368548A1 (en

Inventor

Connie Sanchez Morillo

Gennady N. SMAGIN

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

H Lundbeck AS

Original Assignee

H Lundbeck AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-20

Filing date

2014-12-18

Publication date

2019-09-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014368548(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-18 Application filed by H Lundbeck AS filed Critical H Lundbeck AS

2016-06-30 Publication of AU2014368548A1 publication Critical patent/AU2014368548A1/en

2019-09-19 Application granted granted Critical

2019-09-19 Publication of AU2014368548B2 publication Critical patent/AU2014368548B2/en

Status Ceased legal-status Critical Current

2034-12-18 Anticipated expiration legal-status Critical

Links

230000000694 effects Effects 0.000 title claims abstract description 165
YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title claims abstract description 143
229960002263 vortioxetine Drugs 0.000 title claims abstract description 140
239000003401 opiate antagonist Substances 0.000 title claims abstract description 123
238000011282 treatment Methods 0.000 title abstract description 96
208000020401 Depressive disease Diseases 0.000 title abstract description 51
229940123257 Opioid receptor antagonist Drugs 0.000 title description 6
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical group N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 95
229960005297 nalmefene Drugs 0.000 claims description 94
150000003839 salts Chemical class 0.000 claims description 12
239000000546 pharmaceutical excipient Substances 0.000 claims description 10
241001465754 Metazoa Species 0.000 description 50
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 36
229930006000 Sucrose Natural products 0.000 description 36
239000005720 sucrose Substances 0.000 description 36
150000001875 compounds Chemical class 0.000 description 32
238000000034 method Methods 0.000 description 32
239000003814 drug Substances 0.000 description 30
208000007848 Alcoholism Diseases 0.000 description 21
229940079593 drug Drugs 0.000 description 21
201000007930 alcohol dependence Diseases 0.000 description 20
102000003840 Opioid Receptors Human genes 0.000 description 18
108090000137 Opioid Receptors Proteins 0.000 description 18
239000003981 vehicle Substances 0.000 description 18
230000001684 chronic effect Effects 0.000 description 17
239000000203 mixture Substances 0.000 description 16
238000012360 testing method Methods 0.000 description 16
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 15
229960004801 imipramine Drugs 0.000 description 15
239000000243 solution Substances 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 12
229960003086 naltrexone Drugs 0.000 description 12
208000024891 symptom Diseases 0.000 description 12
UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 11
APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 description 11
229960000938 nalorphine Drugs 0.000 description 11
229960004127 naloxone Drugs 0.000 description 11
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
208000007415 Anhedonia Diseases 0.000 description 10
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 10
229960001736 buprenorphine Drugs 0.000 description 10
239000002552 dosage form Substances 0.000 description 10
OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 description 9
229960000263 levallorphan Drugs 0.000 description 9
-1 nal30 trexone Chemical compound 0.000 description 9
239000005557 antagonist Substances 0.000 description 8
102000048260 kappa Opioid Receptors Human genes 0.000 description 8
239000007788 liquid Substances 0.000 description 8
208000024714 major depressive disease Diseases 0.000 description 8
230000036651 mood Effects 0.000 description 8
230000008450 motivation Effects 0.000 description 8
239000003887 narcotic antagonist Substances 0.000 description 8
239000007787 solid Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 8
108020001588 κ-opioid receptors Proteins 0.000 description 8
239000002775 capsule Substances 0.000 description 7
239000003085 diluting agent Substances 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
235000013305 food Nutrition 0.000 description 7
238000007917 intracranial administration Methods 0.000 description 7
241000283984 Rodentia Species 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
230000007423 decrease Effects 0.000 description 6
201000010099 disease Diseases 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000012458 free base Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000004031 partial agonist Substances 0.000 description 6
208000020016 psychiatric disease Diseases 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
238000010171 animal model Methods 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
230000037396 body weight Effects 0.000 description 5
239000000969 carrier Substances 0.000 description 5
230000000994 depressogenic effect Effects 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
102000051367 mu Opioid Receptors Human genes 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
108020001612 μ-opioid receptors Proteins 0.000 description 5
108010065372 Dynorphins Proteins 0.000 description 4
239000001828 Gelatine Substances 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000009471 action Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000000750 progressive effect Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000002787 reinforcement Effects 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
229920000858 Cyclodextrin Polymers 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
102100024622 Proenkephalin-B Human genes 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000006735 deficit Effects 0.000 description 3
108700023159 delta Opioid Receptors Proteins 0.000 description 3
102000048124 delta Opioid Receptors Human genes 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
230000035622 drinking Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000002313 prodepressive effect Effects 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
206010054089 Depressive symptom Diseases 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
208000001431 Psychomotor Agitation Diseases 0.000 description 2
206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
206010037213 Psychomotor retardation Diseases 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
206010068932 Terminal insomnia Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
238000013019 agitation Methods 0.000 description 2
150000005215 alkyl ethers Chemical class 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
230000008503 anti depressant like effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
ZHPMYDSXGRRERG-DEOSSOPVSA-N aticaprant Chemical compound CC1=CC(C)=CC([C@H]2N(CCC2)CC=2C=CC(OC=3C(=CC(=CC=3)C(N)=O)F)=CC=2)=C1 ZHPMYDSXGRRERG-DEOSSOPVSA-N 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000004040 coloring Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000005286 illumination Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229940125425 inverse agonist Drugs 0.000 description 2
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000001814 pectin Substances 0.000 description 2
229920001277 pectin Polymers 0.000 description 2
235000010987 pectin Nutrition 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
238000011458 pharmacological treatment Methods 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
235000021147 sweet food Nutrition 0.000 description 2
238000012549 training Methods 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
GYWMRGWFQPSQLK-OPHZJPRHSA-N (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydron;chloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 GYWMRGWFQPSQLK-OPHZJPRHSA-N 0.000 description 1
KJXWEKCEAVJWHZ-UHFFFAOYSA-N 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 KJXWEKCEAVJWHZ-UHFFFAOYSA-N 0.000 description 1
125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
206010012374 Depressed mood Diseases 0.000 description 1
102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
108010049140 Endorphins Proteins 0.000 description 1
102000009025 Endorphins Human genes 0.000 description 1
OBSYBRPAKCASQB-UHFFFAOYSA-N Episalvinorin A Natural products COC(=O)C1CC(OC(C)=O)C(=O)C(C2(C3)C)C1(C)CCC2C(=O)OC3C=1C=COC=1 OBSYBRPAKCASQB-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
101100114416 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) con-10 gene Proteins 0.000 description 1
HLMSIZPQBSYUNL-IPOQPSJVSA-N Noroxymorphone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 HLMSIZPQBSYUNL-IPOQPSJVSA-N 0.000 description 1
208000012488 Opiate Overdose Diseases 0.000 description 1
229940127450 Opioid Agonists Drugs 0.000 description 1
208000026251 Opioid-Related disease Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038678 Respiratory depression Diseases 0.000 description 1
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
206010051259 Therapy naive Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000007239 Wittig reaction Methods 0.000 description 1
APSUXPSYBJVPPS-YHMFJAFCSA-N ac1l3op1 Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YHMFJAFCSA-N 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
239000000729 antidote Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000013475 authorization Methods 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000005282 brightening Methods 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
239000006274 endogenous ligand Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000012048 forced swim test Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
239000000380 hallucinogen Substances 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000002632 kappa opiate receptor agonist Substances 0.000 description 1
239000002618 kappa opiate receptor antagonist Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
238000010150 least significant difference test Methods 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229960000677 nalmefene hydrochloride Drugs 0.000 description 1
229950010675 nalmefene hydrochloride dihydrate Drugs 0.000 description 1
ZHVWWEYETMPAMX-PCWWUVHHSA-N naltriben Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3OC=25)O)CC1)O)CC1CC1 ZHVWWEYETMPAMX-PCWWUVHHSA-N 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
210000001009 nucleus accumben Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
239000003402 opiate agonist Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000002688 persistence Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
IQXUYSXCJCVVPA-UHFFFAOYSA-N salvinorin A Natural products CC(=O)OC1CC(OC(=O)C)C2(C)CCC34CC(CC3(C)C2C1=O)(OC4=O)c5occc5 IQXUYSXCJCVVPA-UHFFFAOYSA-N 0.000 description 1
OBSYBRPAKCASQB-AGQYDFLVSA-N salvinorin A Chemical compound C=1([C@H]2OC(=O)[C@@H]3CC[C@]4(C)[C@@H]([C@]3(C2)C)C(=O)[C@@H](OC(C)=O)C[C@H]4C(=O)OC)C=COC=1 OBSYBRPAKCASQB-AGQYDFLVSA-N 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000000862 serotonergic effect Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000003997 social interaction Effects 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000035922 thirst Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
VNGRUFUIHGGOOM-UHFFFAOYSA-N vortioxetine hydrobromide Chemical compound Br.CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 VNGRUFUIHGGOOM-UHFFFAOYSA-N 0.000 description 1
229960004030 vortioxetine hydrobromide Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2014368548A 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features Ceased AU2014368548B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA201300710		2013-12-20
DKPA201300710		2013-12-20
DKPA201400590		2014-10-16
DKPA201400590		2014-10-16
PCT/EP2014/078515 WO2015091833A1 (en)	2013-12-20	2014-12-18	Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Publications (2)

Publication Number	Publication Date
AU2014368548A1 AU2014368548A1 (en)	2016-06-30
AU2014368548B2 true AU2014368548B2 (en)	2019-09-19

Family

ID=52146489

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2014368548A Ceased AU2014368548B2 (en)	2013-12-20	2014-12-18	Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Country Status (14)

Country	Link
US (1)	US10376506B2 (2)
EP (1)	EP3082815B1 (2)
JP (1)	JP6448645B2 (2)
KR (1)	KR20160093025A (2)
CN (1)	CN105828821B (2)
AU (1)	AU2014368548B2 (2)
CA (1)	CA2933733A1 (2)
CL (1)	CL2016001570A1 (2)
ES (1)	ES2694352T3 (2)
IL (1)	IL246253A0 (2)
MX (1)	MX368870B (2)
RU (1)	RU2679661C1 (2)
SG (1)	SG11201604944PA (2)
WO (1)	WO2015091833A1 (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018002115A1 (en)	2016-07-01	2018-01-04	H. Lundbeck A/S	Vortioxetine dosing regimes for fast onset of antidepressant effect
US20210393621A1 (en)	2018-10-26	2021-12-23	The Research Foundation For The State University Of New York	Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3876938A4 (en)	2018-11-06	2022-08-10	Purdue Pharma L.P.	COMPOSITIONS AND METHODS OF ADMINISTRATION OF OPIOID ANTAGONISTS
US11266627B1 (en)	2021-05-04	2022-03-08	Janssen Pharmaceuticals, Inc.	Compositions and methods for the treatment of depression
US12161622B2 (en)	2021-05-04	2024-12-10	Janssen Pharmaceuticals, Inc.	Compositions and methods for the treatment of depression
CN119156211A (zh)	2022-03-07	2024-12-17	杨森制药公司	用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
EP4489730B1 (en)	2022-03-07	2026-01-21	Janssen Pharmaceuticals, Inc.	Compositions comprising aticaprant
WO2025197843A1 (ja) *	2024-03-18	2025-09-25	学校法人東京理科大学	アンヘドニアの治療又は予防用医薬組成物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5817665A (en) *	1993-03-02	1998-10-06	John S. Nagle	Composition and method of treating depression using naloxone or naltrexone in combination with a serotonin reuptake inhibitor
US20020091075A1 (en) *	2000-12-21	2002-07-11	Carlezon Wiliam A.	Treatment of depression
US20030153590A1 (en) *	2001-08-14	2003-08-14	Oy Contral Pharma Ltd	Method of treating alcoholism or alcohol abuse
US20030181475A1 (en) *	2002-03-20	2003-09-25	Euro-Celtique S.A.	Method of administering buprenorphine to treat depression
US20040242974A1 (en) *	2001-08-09	2004-12-02	Hillel Glover	Treatment of refractory depression with an opiate antagonist and an antidepressant
US20070179168A1 (en) *	2005-11-28	2007-08-02	Orexigen Therapeutics, Inc.	Methods of treating anxiety disorders
US20070259939A1 (en) *	2006-05-04	2007-11-08	Accelerated Technologies	Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
WO2014120936A2 (en) *	2013-01-30	2014-08-07	Pharmorx Therapeutics, Inc.	Treatments for depression and other diseases with a low dose agent
WO2014170351A1 (en) *	2013-04-17	2014-10-23	H. Lundbeck A/S	Nalmefene for treatment of patients with mood disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5028612A (en)	1990-03-22	1991-07-02	Hillel Glover	Method for treating emotional numbness
US5013740A (en)	1990-03-22	1991-05-07	Hillel Glover	Method for treating emotional numbness and coma
UA81749C2 (uk)	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US20080045610A1 (en) *	2004-09-23	2008-02-21	Alexander Michalow	Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101432011A (zh) *	2006-02-27	2009-05-13	亚历山大·米哈洛	通过诱导逆适应调节神经递质系统的方法
WO2008066916A1 (en)	2006-11-30	2008-06-05	The Mclean Hospital Corporation	Methods for the treatment of mood disorders
DK2001456T3 (da) *	2006-04-04	2010-04-12	Emodys Gmbh	Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
PL2044043T5 (pl)	2006-06-16	2022-05-02	H. Lundbeck A/S	Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
TW200848411A (en)	2007-03-20	2008-12-16	Lundbeck & Co As H	Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) *	2007-11-13	2009-08-01	Lundbeck & Co As H	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) *	2007-12-14	2009-08-01	Lundbeck & Co As H	4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
ES2564006T3 (es)	2009-05-25	2016-03-17	H. Lundbeck A/S	Preparación de hidrocloruro de nalmefeno a partir de naltrexona
US20120302590A1 (en) *	2009-08-13	2012-11-29	The General Hospital Corporation	Methods and compositions to prevent addiction
PH12012502153A1 (en)	2010-04-30	2013-02-04	Takeda Pharmaceuticals Co	Enteric tablet
SMT201700177T1 (it)	2010-11-05	2017-05-08	H Lundbeck As	Procedimento per la fabbricazione di naltrexone
CA2909506C (en)	2013-04-17	2021-04-20	H. Lundbeck A/S	Nalmefene for treatment of patients with anxiety disorder

2014
- 2014-12-18 MX MX2016007947A patent/MX368870B/es active IP Right Grant
- 2014-12-18 ES ES14818973.1T patent/ES2694352T3/es active Active
- 2014-12-18 US US15/105,701 patent/US10376506B2/en active Active
- 2014-12-18 SG SG11201604944PA patent/SG11201604944PA/en unknown
- 2014-12-18 EP EP14818973.1A patent/EP3082815B1/en active Active
- 2014-12-18 CN CN201480069586.5A patent/CN105828821B/zh active Active
- 2014-12-18 KR KR1020167016182A patent/KR20160093025A/ko not_active Withdrawn
- 2014-12-18 JP JP2016540981A patent/JP6448645B2/ja active Active
- 2014-12-18 WO PCT/EP2014/078515 patent/WO2015091833A1/en not_active Ceased
- 2014-12-18 RU RU2016123972A patent/RU2679661C1/ru not_active IP Right Cessation
- 2014-12-18 AU AU2014368548A patent/AU2014368548B2/en not_active Ceased
- 2014-12-18 CA CA2933733A patent/CA2933733A1/en not_active Abandoned
2016
- 2016-06-15 IL IL246253A patent/IL246253A0/en unknown
- 2016-06-17 CL CL2016001570A patent/CL2016001570A1/es unknown

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5817665A (en) *	1993-03-02	1998-10-06	John S. Nagle	Composition and method of treating depression using naloxone or naltrexone in combination with a serotonin reuptake inhibitor
US20020091075A1 (en) *	2000-12-21	2002-07-11	Carlezon Wiliam A.	Treatment of depression
US20040242974A1 (en) *	2001-08-09	2004-12-02	Hillel Glover	Treatment of refractory depression with an opiate antagonist and an antidepressant
US20030153590A1 (en) *	2001-08-14	2003-08-14	Oy Contral Pharma Ltd	Method of treating alcoholism or alcohol abuse
US20030181475A1 (en) *	2002-03-20	2003-09-25	Euro-Celtique S.A.	Method of administering buprenorphine to treat depression
US20070179168A1 (en) *	2005-11-28	2007-08-02	Orexigen Therapeutics, Inc.	Methods of treating anxiety disorders
US20070259939A1 (en) *	2006-05-04	2007-11-08	Accelerated Technologies	Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
WO2014120936A2 (en) *	2013-01-30	2014-08-07	Pharmorx Therapeutics, Inc.	Treatments for depression and other diseases with a low dose agent
WO2014170351A1 (en) *	2013-04-17	2014-10-23	H. Lundbeck A/S	Nalmefene for treatment of patients with mood disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADELL ALBERT, "Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety", I DRUGS: THE INVESTIGATIONAL DRUGS JOURNAL, CURRENT DRUGS LTD, GB, (2010-12), vol. 13, no. 12, pages 900 - 910 *

Also Published As

Publication number	Publication date
KR20160093025A (ko)	2016-08-05
WO2015091833A1 (en)	2015-06-25
EP3082815B1 (en)	2018-10-03
AU2014368548A1 (en)	2016-06-30
JP6448645B2 (ja)	2019-01-09
MX368870B (es)	2019-10-21
CN105828821B (zh)	2019-04-09
MX2016007947A (es)	2016-09-09
US10376506B2 (en)	2019-08-13
SG11201604944PA (en)	2016-07-28
CN105828821A (zh)	2016-08-03
JP2016540030A (ja)	2016-12-22
CA2933733A1 (en)	2015-06-25
EP3082815A1 (en)	2016-10-26
ES2694352T3 (es)	2018-12-20
IL246253A0 (en)	2016-07-31
US20160310488A1 (en)	2016-10-27
RU2016123972A (ru)	2018-01-25
RU2679661C1 (ru)	2019-02-12
CL2016001570A1 (es)	2016-12-09

Legal Events

Date	Code	Title	Description
2020-01-16	FGA	Letters patent sealed or granted (standard patent)
2021-07-15	MK14	Patent ceased section 143(a) (annual fees not paid) or expired

Publication	Publication Date	Title
AU2014368548B2 (en)	2019-09-19	Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP3552604B1 (en)	2020-12-16	Compositions for treating drug addiction and improving addiction-related behavior
WO2007005716A2 (en)	2007-01-11	Methods of treatment and compositions for use thereof
US10517841B1 (en)	2019-12-31	Compositions and methods for treating respiratory depression with fenfluramine
JP2021523228A (ja)	2021-09-02	物質乱用の治療方法
CN1527711A (zh)	2004-09-08	用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物
H Rezvani et al.	2012	Novel medication targets for the treatment of alcoholism: preclinical studies
US20070053976A1 (en)	2007-03-08	Novel combination of drugs as antidepressant
BR102015011079A2 (pt)	2016-03-29	palmitoiletanolamida em forma não micronizada, em forma micronizada (pea-m), em forma ultramicronizada (pea-um) ou misturas das mesmas e composição farmacêutica ou veterinária
JPWO2008120562A1 (ja)	2010-07-15	帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法
HK1229240B (en)	2019-11-08	Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
HK1229240A1 (en)	2017-11-17	Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
JP2012500248A (ja)	2012-01-05	不安障害の治療
JP2015520145A (ja)	2015-07-16	呼吸抑制の治療
EP1942891B1 (en)	2011-03-23	Novel combination of drugs as antidepressant
ES2975138T3 (es)	2024-07-03	Uso de 2-fenil-6-(1H-imidazol-1-il) quinazolina para la prevención del abuso y de los efectos secundarios de al menos un opioide
US20110046173A1 (en)	2011-02-24	Combination analgesic opioid pain therapy
US20160058753A1 (en)	2016-03-03	Nalmefene for Treatment of Patients with Mood Disorder
WO2024194263A1 (en)	2024-09-26	Serotonin 5ht2a receptor antagonist for use in treating side effects resulting form mu opioid receptor agonist overdose
KR20190120212A (ko)	2019-10-23	알코올 사용 장해의 치료약
JPWO2008102859A1 (ja)	2010-05-27	不安障害の予防および／または治療薬
JP2020517730A (ja)	2020-06-18	心的外傷後ストレス障害を治療するための方法